Follow-On Offering

Healthcare
Follow-On Offering

Summary

Baird served as a co-manager on this offering

About

TESARO, Inc. (“TESARO” or the “Company”) (NASDAQ: TSRO) recently completed a follow-on offering of 3,755,000 shares of common stock at a price of $51.00 per share, generating gross proceeds of approximately $192 million. The Company intends to use the net proceeds to fund potential commercialization activities for oral rolapitant, clinical trials for IV rolapitant, niraparib and other product candidates, to carry out its immuno-oncology platform strategy, and for working capital and general corporate purposes.

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and is currently developing three clinical-stage product candidates, rolapitant (in registration), niraparib (phase 3) and TSR-011 (phase ½). TESARO is headquartered in Waltham, Massachusetts.

For additional information about this transaction, please contact:

David Schechner +1 (617) 426-5424
Ryan Mausehund +1 (650) 858-3817
Lance Lange +1 (414) 765-7079
Vip Patel +1 (414) 765-3802
Satoshi Matsumoto +1 (312) 609-5446
Brian Thomas +1 (415) 627-3275
Healthcare
Follow-On Offering
Date
March 2015
Company
TESARO, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share